Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086021 | 0.89 | CYP2C19 (0.55) | CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL13631908 | 0.81 | CYP3A4 (0.43) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL10066408 | 0.80 | CYP3A4 (0.43) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL8389339 | 0.74 | CYP2C9 (0.42) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL18680881 | 0.73 | CYP3A4 (0.55) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL18680974 | 0.72 | CYP3A4 (0.52) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL12342306 | 0.72 | CYP3A4 (0.39) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL18680638 | 0.71 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL12655351 | 0.71 | CYP3A4 (0.71) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL288426 | 0.70 | CYP2C19 (0.78) | CYP1A2CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, PRKACA, RAF1 | CYP1A2 4247/4885CYP3A4 3358/4885CYP2C19 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.